BioXcel Therapeutics, Inc. (BTAI) › Cash & EquivalentsBioXcel Therapeutics, Inc. (BTAI) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2017-12-31: $887.0K2018-12-31: $42.56M2019-12-31: $32.43M2020-12-31: $213.12M2021-12-31: $232.97M2022-12-31: $193.72M2023-12-31: $65.22M2024-12-31: $29.85M2025-12-31: $28.41M$28.41M2017-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$28.41M-4.8%2026-03-27Balance as of period end2024-12-31$29.85M-54.2%2026-03-27Balance as of period end2023-12-31$65.22M-66.3%2025-03-28Balance as of period end2022-12-31$193.72M-16.8%2024-03-22Balance as of period end2021-12-31$232.97M+9.3%2023-03-16Balance as of period end2020-12-31$213.12M+557.2%2022-03-11Balance as of period end2019-12-31$32.43M-23.8%2021-03-12Balance as of period end2018-12-31$42.56M+4698.8%2020-03-09Balance as of period end2017-12-31$887.0K—2019-03-12Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)